Corrigendum to: First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors: First trimester combined screening for early and late preeclampsia (Prenatal Diagnosis, (2015), 35, 2, (183-191), 10.1002/pd.4519);First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors

Prenatal Diagnosis

Volumn 35, Issue 2, 2015, Pages 183-191

  Crovetto, Francesca ^a,b   Figueras, Francesc ^a   Triunfo, Stefania ^a   Crispi, Fatima ^a   Rodriguez Sureda, Victor ^c   Dominguez, Carmen ^c   Llurba, Elisa ^c,d   Gratacós, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF MILAN   (Italy)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CHORIONIC GONADOTROPIN; FMS LIKE TYROSINE KINASE 1; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; CHORIONIC GONADOTROPIN BETA SUBUNIT; PAPPA1 PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD CHEMISTRY; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DOPPLER FLOWMETRY; FALSE POSITIVE RESULT; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HORMONE BLOOD LEVEL; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PREECLAMPSIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; UTERINE ARTERY; BLOOD; BLOOD PRESSURE; ECHOGRAPHY; MASS SCREENING; METABOLISM; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREDICTIVE VALUE; PREGNANCY;

UTA;

ADULT; BLOOD PRESSURE; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; HUMANS; MASS SCREENING; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; UTERINE ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84922010010     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.5358     Document Type: Erratum

References (33)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
3. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30(Suppl A):S32-7.
4. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143-8.
5. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402-14.
6. Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141-6.
7. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104:1367-91.
8. Cuckle HS. Screening for pre-eclampsia--lessons from aneuploidy screening. Placenta 2011;32(Suppl):S42-8.
9. Forest JC, Charland M, Masse J, et al. Candidate biochemical markers for screening of pre-eclampsia in early pregnancy. Clin Chem Lab Med 2012;50:973-84.
10. Poon LC, Kametas NA, Chelemen T, et al. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010;24:104-10.
11. North RA, McCowan LM, Dekker GA, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ 2011;342:d1875.
12. Poon LC, Kametas NA, Maiz N, et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009;53:812-8
13. Poon LC, Stratieva V, Piras S, et al. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn 2010;30:216-23.
14. Scazzocchio E, Figueras F, Crispi F, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013;208:203.e1-e10.
15. Spencer K, Yu CK, Cowans NJ, et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005;25:949-53.
16. Akolekar R, Zaragoza E, Poon LC, et al. Maternal serum placental growth factor at 11+0 to 13+6weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:732-9.
17. Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
18. Poon LC, Syngelaki A, Akolekar R, et al. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther 2013;33:16-27.
19. Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33:8-15.
20. Parra-Cordero M, Rodrigo R, Barja P, et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol 2013;41:538-44.
21. Crovetto F, Figueras F, Triunfo S, et al. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy. Fetal Diagn Ther Fetal 2014. DOI:10.1159/000358302.
22. Robinson HP, Fleming JE. A critical evaluation of sonar " crown-rump length" measurements. Br J Obstet Gynaecol 1975;82:702-10.
23. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV.
24. Figueras F, Meler E, Iraola A, et al. Customized birthweight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol 2008;136:20-4.
25. Gregg AR, Weiner CP. " Normal" umbilical arterial and venous acid-base and blood gas values. Clin Obstet Gynecol 1993;36:24-32.
26. Gomez O, Figueras F, Fernandez S, et al. Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet Gynecol 2008;32:128-32.
27. Casals E, Aibar C, Martinez JM, et al. First-trimester biochemical markers for Down syndrome. Prenat Diagn 1999;19:8-11.
28. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353(9164):1547-57.
29. Park FJ, Leung CHY, Poon LC, et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease in pregnancy. Aust New Zeal J Obstet Gynaecol 2013;53:532-9.
30. Baumann MU, Bersinger NA, Mohaupt MG, et al. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008;199:266 e1-6.
31. Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279-87.
32. Akolekar R, de Cruz J, Foidart JM, et al. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13weeks of gestation in preeclampsia. Prenat Diagn 2010;30:191-7.
33. Biesheuvel CJ, Vergouwe Y, Oudega R, et al. Advantages of the nested case-control design in diagnostic research. BMC Med Res Methodol 2008;8:48-54.